Can Stoke Therapeutics (STOK) Justify Its Valuation Following Long Term Zorevunersen Data?

Stoke Therapeutics (STOK) drew fresh attention after presenting more than 5 years of clinical data for zorevunersen at the 16th European Epilepsy Congress. The company highlighted seizure reduction, cognitive benefits and a generally consistent safety profile in Dravet syndrome.

Investors have pushed Stoke Therapeutics to a US$29.34 share price after a long run where total shareholder return over three years has been very large. This comes even though the stock is down 11% on a 1 month share price basis and roughly flat over 90 days, as the recent data presentations and conference appearances are digested and expectations around future risk and reward are reassessed.

Spot fresh biotech momentum by scanning hand-picked genetic medicine players alongside Stoke Therapeutics with the 39 healthcare AI stocks.

After a huge three year run that lifted Stoke Therapeutics to US$29.34, near term returns have cooled. Does the current balance of pipeline risk and potential reward still lean in favour of new buyers or existing holders?

Most Popular Narrative: 34.9% Undervalued

Against Stoke Therapeutics' last close of $29.34, the most followed narrative points to a fair value of $45.10, leaving a wide valuation gap that rests on aggressive revenue and margin assumptions being met over time.

The shift toward disease-modifying therapies in severe epilepsies raises the regulatory and evidentiary bar. Any delay, additional data requirements, or failure to show clear differentiation versus emerging competitors could push out potential launch timing and limit peak revenue.

Read the complete narrative. Read the complete narrative.

Want to know what sits behind that higher fair value for Stoke Therapeutics? The widely followed thesis leans on rapid top line expansion, improving margins and a rich future earnings multiple to support that price. Curious which specific growth, profitability and discount rate inputs have to line up for this to hold? The full narrative lays out the precise financial path that needs to play out.

Result: Fair Value of $45.10 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, the Stoke Therapeutics story can break if the EMPEROR Phase 3 trial fails to echo earlier seizure and cognition signals, or if regulators push out approval timelines and extend cash burn.

Find out about the key risks to this Stoke Therapeutics narrative.

Another angle on Stoke Therapeutics valuation

On one side, the consensus narrative and analyst targets frame Stoke Therapeutics as 34.9% undervalued against a fair value of $45.10. On the other, the Simply Wall St DCF model is far more optimistic, with a future cash flow value of $327.61 that implies a very large upside gap. Which set of expectations appears more realistic for you?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

Mixed messages from Stoke Therapeutics so far? If you want to move fast and still think clearly, start with the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Stoke Therapeutics?

If you stop with Stoke Therapeutics, you risk missing other stocks that better match your risk, income and quality preferences across the market.

• Target potential mispricing by scanning a curated pool of quality opportunities through the 33 high quality undervalued stocks.
• Boost portfolio resilience by focusing on businesses with strong finances using the list of solid balance sheet and fundamentals (23 results).
• Unearth lesser-known prospects that still pass strict fundamental checks with the 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com